BR112012023518A2 - Composição farmacêutica gastro- resistente compactada,monolítica, composição farmaceutica método para tratar um disturbio digestivo e método de controle da esteatorreia - Google Patents

Composição farmacêutica gastro- resistente compactada,monolítica, composição farmaceutica método para tratar um disturbio digestivo e método de controle da esteatorreia

Info

Publication number
BR112012023518A2
BR112012023518A2 BR112012023518A BR112012023518A BR112012023518A2 BR 112012023518 A2 BR112012023518 A2 BR 112012023518A2 BR 112012023518 A BR112012023518 A BR 112012023518A BR 112012023518 A BR112012023518 A BR 112012023518A BR 112012023518 A2 BR112012023518 A2 BR 112012023518A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
monolithic
compact
steatorrhea
gastro
Prior art date
Application number
BR112012023518A
Other languages
English (en)
Inventor
Alexandru Mateescu Mircea
Janet Bustos Ingry
Dumoulin Yves
Ispas Szabo Pompilia
Original Assignee
Aptalis Pharma Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44648484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012023518(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aptalis Pharma Canada Inc filed Critical Aptalis Pharma Canada Inc
Publication of BR112012023518A2 publication Critical patent/BR112012023518A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIÇÃO FARMACÊUTICA GASTRO-RESISTENTE COMPACTADA, MONOLÍTICA, COMPOSIÇÃO FARMACÊUTICA COMPACTADA DE MULTI-CAMADAS, PROCESSO PARA PREPARAR A COMPOSIÇÃO FARMACÊUTICA, MÉTODO PARA TRATAR UM DISTÚRBIO DIGESTIVO E MÉTODO DE CONTROLE DA ESTEATORREIA. A presente invenção geralmente refere-se a composições farmacêuticas compactadas (tais como comprimidos) compreendendo uma ou mais enzimas, em que a composição é monolítica ou multiparticulada (tais como mini-comprimidos, micro-comprimidos ou grânulos), ou em que a composição tem múltiplas camadas com a camada externa contendo uma ou mais enzimas.
BR112012023518A 2010-03-19 2011-03-18 Composição farmacêutica gastro- resistente compactada,monolítica, composição farmaceutica método para tratar um disturbio digestivo e método de controle da esteatorreia BR112012023518A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31581410P 2010-03-19 2010-03-19
PCT/IB2011/000579 WO2011114224A1 (en) 2010-03-19 2011-03-18 Gastro-resistant enzyme pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BR112012023518A2 true BR112012023518A2 (pt) 2017-10-03

Family

ID=44648484

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012023518A BR112012023518A2 (pt) 2010-03-19 2011-03-18 Composição farmacêutica gastro- resistente compactada,monolítica, composição farmaceutica método para tratar um disturbio digestivo e método de controle da esteatorreia

Country Status (13)

Country Link
US (1) US20130337062A1 (pt)
EP (1) EP2547331A4 (pt)
JP (1) JP2013522284A (pt)
KR (1) KR20130050923A (pt)
CN (1) CN102883712A (pt)
AU (1) AU2011228743A1 (pt)
BR (1) BR112012023518A2 (pt)
CA (1) CA2793685A1 (pt)
CL (1) CL2012002605A1 (pt)
MX (1) MX2012010755A (pt)
RU (1) RU2012142134A (pt)
SG (1) SG184095A1 (pt)
WO (1) WO2011114224A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
NZ579047A (en) 2007-02-20 2012-03-30 Aptalis Pharma Ltd Stable digestive enzyme compositions
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
PL2621476T5 (pl) 2010-10-01 2022-06-06 Société des Produits Nestlé S.A. Dojelitowe powlekane preparaty pankrelipazy o niskiej mocy
ES2558756T3 (es) 2011-08-08 2016-02-08 Aptalis Pharma Limited Método para la prueba de disolución de composiciones sólidas que contienen enzimas digestivas
US10993996B2 (en) 2013-08-09 2021-05-04 Allergan Pharmaceuticals International Limited Digestive enzyme composition suitable for enteral administration
CN106659773A (zh) * 2013-11-05 2017-05-10 阿勒根制药国际有限公司 高效的胰酶药物组合物
WO2015193730A1 (en) * 2014-06-19 2015-12-23 Aptalis Pharma Ltd. Methods for removing viral contaminants from pancreatic extracts
DE102017104501A1 (de) 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutische Zusammensetzung umfassend einen Träger und einen Überzug enthaltend wenigstens eine Lipase
DE102017104482A1 (de) 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutische Zusammensetzung umfassend Pankreatin und einen lipasehaltigen Überzug

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991180A (en) * 1972-03-06 1976-11-09 Rohm And Haas Company Stabilization of internally administered pancreatic lipase
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
GB8421210D0 (en) * 1984-08-21 1984-09-26 Celltech Ltd Polypeptide and polypeptide composition
IT1205716B (it) * 1987-01-21 1989-03-31 Samil Spa Procedimento per la preparazione di microsfere gastroresistenti ed enterosolubili di enzima digestivo e preparato faramceutico a microsfere cosi' prodotto
ES2236738T3 (es) * 1995-05-31 2005-07-16 Medzyme N.V. Composicion para mejorar la digestibilidad y la utilizacion de nutrientes.
KR19990072826A (ko) * 1998-02-26 1999-09-27 우재영 판크레아틴장용코팅과립의제조방법
AR032392A1 (es) * 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
US8071089B2 (en) * 2005-11-01 2011-12-06 Bio-Cat, Inc. Composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrosis as well as people suffering from pancreatic lipase insufficiency
NZ579047A (en) * 2007-02-20 2012-03-30 Aptalis Pharma Ltd Stable digestive enzyme compositions
EP2509635A4 (en) * 2009-12-08 2013-09-18 Depomed Inc GASTRORETENTIVE PHARMACEUTICAL COMPOSITIONS FOR THE EXTENDED RELEASE OF POLYPEPTIDES

Also Published As

Publication number Publication date
EP2547331A1 (en) 2013-01-23
KR20130050923A (ko) 2013-05-16
MX2012010755A (es) 2013-03-08
JP2013522284A (ja) 2013-06-13
CN102883712A (zh) 2013-01-16
RU2012142134A (ru) 2014-04-27
US20130337062A1 (en) 2013-12-19
SG184095A1 (en) 2012-10-30
WO2011114224A1 (en) 2011-09-22
AU2011228743A1 (en) 2012-10-11
CA2793685A1 (en) 2011-09-22
EP2547331A4 (en) 2014-04-30
CL2012002605A1 (es) 2013-10-04

Similar Documents

Publication Publication Date Title
BR112012023518A2 (pt) Composição farmacêutica gastro- resistente compactada,monolítica, composição farmaceutica método para tratar um disturbio digestivo e método de controle da esteatorreia
PH12020550450A1 (en) Certain chemical entities, compositions and methods
BR112013000107A2 (pt) aminopirazoloquinazolinas
BR112015002152A2 (pt) pirróis substituídos ativos como inibidores de quinases
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
BR112014030812A2 (pt) "compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr"
BR112012010270A2 (pt) mentisulfonilmetano (msm) para tratamento de micro-organismos resistentes a fármaco
MX350875B (es) Formas de dosificacion farmaceutica de liberacion controlada.
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112013026137A8 (pt) pirimidinil-pirróis substituídos ativos como inibidores da quinase
CL2014002077A1 (es) Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple.
BR112012024678A2 (pt) composto, composição farmacêutica, e, métodos para tratar e para previnir uma doença ou distúrbio
BR112012028290A2 (pt) desintoxicação de acetato derivado de biomassa via conversão metabólica em etanol, acetona, isopropanol ou acetato de etila
BRPI0508557A (pt) composição farmacêutica que compreende pimobendan
BR112014004465A2 (pt) compostos e composições como inibidores de pdgfr cinase
CL2012002356A1 (es) Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras.
WO2011139489A3 (en) Compounds that modulate intracellular calcium
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
BR112015003729A2 (pt) composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
EA201590835A1 (ru) Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием
EP2571357A4 (en) CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINAS MODULATION
UY32177A (es) Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
WO2012027710A3 (en) Compounds that modulate intracellular calcium
BR112012005837A8 (pt) Composição de enzimas digestivas em multipartículas, forma de dosagem, método para o tratamento da dor proveniente da pancreatite, método para o tratamento da dor proveniente da pancreatite e da insuficiência pancreática, método para o tratamento da insuficiência pancreática exócrina e método para o tratamento da dor pancreática
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]